Tocagen Inc

Tocagen — Forte Biosciences — Investor Presentation (June 2020)

17 slides from Tocagen's investor presentation, Jun 26, 2020

  1. Slide 1: Forte Biosciences Corporate Presentation June 2020

    Forte biosciences TOPICAL live biotherapeutic for the treatment of Inflammatory skin disease Corporate PRESENTATION June 2020 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Act of 1995, known as the PSLRA. These inc

  3. Slide 3: Summary of Forte Biosciences: FB-401

    Summary OF Forte Biosciences: FB-401 – POTENTIAL first-in-class topical live biotherapeutic for the treatment of inflammatory Skin disease Late-stage CLINICAL Asset Phase 2a trial in atopic dermatitis completed including pediatrics 3 years and older, FB-401 was well tolerated and demonstrated clinic

  4. Slide 4: Overview of FB-401

    FORTE BIOSCIENCES: Overview of FB-401 FB-401 drug product consists of 3 therapeutic bacterial strains of commensal gram negative R. mucosa specifically selected based on screening for impact on inflammatory skin disease parameters Topical application of the specifically selected therapeutic bacteria

  5. Slide 5: Experienced management and advisory teams

    EXPERIENCED management and advisory Teams Paul Wagner, Ph.D. – CEO Forte BioSciences team has extensive experience in microbial manufacturing, quality, regulatory and clinical development in dermatology Dan Burge, MD – Head of Clinical Development Eric Emery – Head of Downstream Manufacturing Hank T

  6. Slide 6: Atopic dermatitis

    Atopic dermatitis Atopic dermatitis (AD) is characterized by itching, a scaly rash, dry skin, and cutaneous sensitization to allergens. The underlying pathology of AD consists of a triad of defective skin barrier function, susceptibility to Staphylococcus aureus skin infection, and immune imbalance

  7. Slide 7: Skin microbiome

    SKIN MICROBIOME Dreno et al, European Academy of Dermatology and Venerology 2016, 30, 2038-2047 Kong HH et al. Genome research. 2012;22(5):850-859 The skin is a complex barrier organ characterized by symbiotic relationship between microbial communities and host tissue via complex signals provided by

  8. Slide 8: Skin microbiome differences in atopic dermatitis

    SKIN MICROBIOME differences in atopic dermatitis Myles IA, Williams KW, Reckhow JD, et al. JCI Insight. 2016;1(10) Kong HH et al. Genome research. 2012;22(5):850-859 Genetic-based microbiome identification revealed significant differences in the Gram-negative skin biome between atopic dermatitis (AD

  9. Slide 9: Phase 2a first human study of FB-401

    Phase 2A First HUMAN study of FB-401 - cutaneous live biotherapeutic for the treatment of atopic dermatitis Drug product: FB-401 (3 specifically selected therapeutic R. mucosa strains) lyophilized and reconstituted with sterile water in single-use, self-administered spray Design: Phase 1/2a enrolled

  10. Slide 10: Cohort completed treatment of adults with AD

    Cohort 1 completed treatment of 10 adults with AD Ten adult AD patients ages 18 years and older were treated in 2-week intervals with 103, 104, and then 105 CFU of R mucosa twice per week (BIW) for a total of 6 weeks

  11. Slide 11: Dose-dependent improvements observed in adult cohort of Phase 1/2a study

    Statistically significant, Dose-dependent improvements observed in adult cohort of PHASE 1/2a Study (A) Intensity of AD disease was measured in a blinded manner using SCORAD measures of dryness, redness, lichenification, excoriation, crusting and edema (0-3 scale for each measure) (B) Subjective pru

  12. Slide 12: Cohort 2: FB-401 treatment of children with AD

    Cohort 2: FB-401 Treatment of 20 Children with AD 20 pediatric/adolescent patients with active AD: First 5, ages 7-17 Remainder, ages 3-17 Baseline SCORAD >10 Design: Treat AD-involved skin with FB-401 103 CFU BIW for 4 weeks 104 CFU BIW for 4 weeks 105 CFU BIW for 4 weeks 105 CFU QOD for 4 weeks Ef

  13. Slide 13: Data from first pediatric patients shows activity across multiple parameters

    Data from First 5 pediatric patients Shows Activity Across multiple parameters SCORAD score statistically significantly improved (A,B) 4/5 show more than 50% improvement and strong trend towards improvement in 5th patient Pruritus shows statistically significant improvement (C) Both SCORAD and pruri

  14. Slide 14: Treatment with FB-401 demonstrates significant improvement

    treatment with FB-401 demonstrates significant improvement Myles et al, JCI Insight, 2018;3(9):e120608

  15. Slide 15: Planned FB-401 randomized Phase 2 study

    Planned FB-401 Randomized Phase 2 Study CONFIDENTIAL Randomized, placebo-controlled, multi-center study Includes children (2 years and older), adolescents and adults with mild to moderate atopic dermatitis Approximately 124 subjects randomized 1:1 to receive FB-401 or placebo for 16 weeks Endpoints

  16. Slide 16: Intellectual property overview

    Intellectual property overview Exclusive license to NIH-owned patent family focused on treatment of AD with a consortia of gram negative bacteria from healthy donors Patent coverage through at least 2037 7 US patents issued Entered in 10 Ex-US jurisdictions Europe, China, Canada, Japan, South Korea,

  17. Slide 17: Summary of Forte Biosciences: FB-401

    Summary OF Forte Biosciences: FB-401 – POTENTIAL first-in-class topical live biotherapeutic for the treatment of inflammatory Skin disease Late-stage CLINICAL Asset Phase 2a trial in atopic dermatitis completed including pediatrics 3 years and older, FB-401 was well tolerated and demonstrated clinic

Forte Biosciences — Investor Presentation (June 2020) on 6ix